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Abstract
BACKGROUND: Ibritumomab is an 90Yttrium (90Y) labelled radio-
immunoconjugate registered to treat follicular lymphoma relaps-
ing or refractory after Rituximab therapy. Combining the speci-
ficity of anti CD20 monoclonal antibodies with the efficacy of ra-
diotherapy, it is particularly effective in patients with advanced
stages of disease with generalized lymphadenopathy.
MATERIAL AND METHODS: Twenty-one patients with follic-
ular lymphoma, after failing 2–5 lines of previous treatment,
were subjected to radioimmunotherapy in three Polish Lym-
phoma Research Group (PLRG) centres. Ibritumomab infu-
sion was followed by 2 doses of Rituximab (250 mg/m2 at
day –7 and 0) to enhance its biodistribution. Radioimmuno-
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conjugate was prepared in the Nuclear Medicine Departments
of participating centres based on patient weight and full blood
count results (14.8 MBq/kg, max 1200 MBq, reduced to 11.1
MBq/kg in cases with blood platelet 100 000–150 000 or leu-
kocytes 1500–2000).
14.8 MBq/kg (0.4 mCi/kg)
100 thousand to 149 thousand/mm3 platelets
11.1 MBq/kg (0.3 mCi/kg)
RESULTS: The primary endpoint of the study was the assess-
ment of response rate and haematological toxicity. Objective
responses were observed in all patients, with 10 partial and 12
complete regressions. Cytopenia, starting 3–4 weeks after ra-
dioimmunotherapy, reflected haematological toxicity — the only
important side effect. Thrombocytopenia was more pronounced,
with platelet counts of < 50,000/ul in every second patient. One
patient developed myelodysplastic syndrome 21 months after
the procedure. After the medium time of follow up over 2 years,
2 patients died. Median progression free survival (secondary
study endpoint) was 15 months.
CONCLUSIONS: Ibritumomab radioimmunotherapy is an effi-
cient method of palliation treatment of heavily pre-treated follic-
ular lymphoma patients, failing numerous previous treatment
lines. Earlier application increases the number of complete re-
sponses and prolongs progression free survival.
Key words: radioimmunotherapy, 90Y-ibritumomab
tiuxetan (Zevalin), follicular lymphoma
Introduction
Zevalin (ibritumomab tiuxetan, IDEC-Y2B8) is a murine IgG1
kappa monoclonal antibody conjugated to tiuxetan (MXDTPA) that
chelates yttrium or indium and is directed against the CD 20 mol-
ecules of B-lymphocytes. It was the first radioimmunoconjugate
registered by the U.S. Food and Drug Administration (FDA) for
lymphoma therapy, and the only one registered so far in Europe
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for follicular lymphoma (FL), refractory or relapsing after Ritu-
ximab. Our Polish experience in radioimmunotherapy (RIT) is based
on over 60 patients treated by the Polish Lymphoma Research
Group (PLRG) centres: 21 FL further described in this paper,
36 mantle cell lymphomas included in a PLRG MCL1 trial and 9
transformed lymphomas after autologous stem cell transplanta-
tion with a Zevalin containing conditioning regimen. During the
last 3 years, a network of collaborating centres (nuclear medicine
and haematology departments) has been developed to deal with
the rather complicated logistics and to make the therapy method
available to patients from all over the country.
Zevalin — mechanism of action
Radiolabelled monoclonal antibodies administered intrave-
nously attach to CD20 (cluster differentiation), an antigen present
on the surface of B-lymphocytes. In lymphoma patients, after
a short distribution phase, most of the antibodies are bound in
the tumour. Each of them is in fact a potent source of local radio-
therapy damaging several adjacent cells and structures. In the
tissues, the average penetration range of beta particles emitted
by 90Y is 5.3 mm; therefore, Zevalin is also effective in partly fi-
brosed, poorly vascularised lymph nodes. Even then, the best
results are achieved if lymphoma infiltrates do not exceed 5–7
cm. RIT may be offered only to patients without substantial blood
and bone marrow involvement (CD20 positive cells must be be-
low 25%) to prevent irreversible stem cell damage. Circulating
lymphoma cells and normal B-lymphocytes also bind to ibritu-
momab, altering it’s biodistribution and increasing toxicity of the
procedure; therefore, their CD20 antigens have to be saturated
by an unconjugated antibody, Rituximab, infused before radio-
immunotherapy. Ibritumomab binds to lymphoma infiltrates all
over the body, so its anti-tumour effect resembles total body
irradiation (TBI) — one of the bone marrow transplant condition-
ing regimens. Ibritumomab biodistribution was confirmed by
imaging studies performed while developing the protocol in the
US, where the first of the two doses of antibody were labelled
with a gamma emitter (indium-111). Biodistribution results were
highly reproducible in typical cases (in a retrospective analysis,
the treatment plan was changed in less than 2% of more than
900 patients [1]). Therefore, in Europe indium imaging is no longer
regarded as necessary. Dosimetry is based only on patients'
weight and results of a full blood count (FBC). Biodistribution
may be altered in patients with a large tumour mass due to
a “sink phenomenon” when most of the antibodies are bound
i.e. in a massive splenomegaly. Although ibritumomab is a mon-
oclonal antibody, its immunological mechanisms, like comple-
ment mediated cytotoxicity (CDC), play only a minor role as its
dose is relatively small (nearly 400 times less than a standard
dose of Rituximab). The effect of antibody mediated cellular to-
xicity (ADCC) is also moderate, as participating immunocompe-
tent cells are likely to be killed in the first place. To summarize,
ibritumomab RIT is a very clever way to deliver systemic radio-
therapy, working best in patients with a disseminated nodal dis-
ease and without substantial bone marrow involvement.
Follicular lymphoma (FL)
Follicular lymphoma (FL) — a well-characterized disease entity
— is the second most common form of non-Hodgkin’s lymphoma
(NHL). Its frequency varies from over 30% of NHL in the US, through
15–25% in Western Europe to 5% in the Far East. A Polish Lympho-
ma Research Group (PLRG) epidemiologic survey, performed on
1060 NHL cases diagnosed in the Małopolska Region in the last
3 years [2], revealed unexpectedly low incidence of FL in Poland (5%).
This unexpected trend was later confirmed in a national survey of
over 5000 cases. Upon diagnosis, most patients are already in the
advanced clinical stage, with at least some degree of bone marrow
involvement. Other extranodular manifestations are rare. The clini-
cal course of follicular lymphoma is variable: in most cases, the
disease is indolent and slowly progressive, characterized by sub-
sequent chemosensitive relapses. The average overall survival (OS)
exceeds eight years, but there seems to be no plateau on the sur-
vival curve. At least 30% of patients are refractory to therapy, re-
lapse early or transform to diffuse large B cell lymphoma (DLBCL).
Prognosis
Prognosis could be predicted by assessing simple clinical risk
factors such as age (> 60 vs. < 60), Ann Arbor stage classification
(III–IV vs. I–II), haemoglobin level (< 12 g/dL vs. > 12 g/dL), num-
ber of nodal areas involved (> 4 vs. < 4) and serum lactate dehy-
drogenase enzyme (LDH) level (> normal vs. < normal). Estimat-
ed ten-year survival is 70%, 50% and 35% for low, intermediate and
high risk groups, respectively, defined as 0–1, 2 and 3 or more risk
factors [3]. Although the Follicular Lymphoma International Prog-
nostic Index (FLIPI) is an extremely simple and reproducible prog-
nostic index, based on easily available clinical data, it does not
indicate patients who will transform to DLBCL.
Follicular lymphoma treatment options
Treatment options of FL include: observation (wait and watch
policy is still fully justified in elderly individuals with low dynamics of
the disease), monotherapy with alkylating agents or purine nucleo-
side analogues, radiation therapy, combination chemotherapy, in-
terferon, monoclonal antibodies and autologous or allogenic stem
cell transplantation. Introducing combination chemotherapy had
a moderate, but yet existing, positive impact on OS [4], prolonging
it from 84 to 93 months. In the past decade, several well-docu-
mented phase III studies (over 7000 patients randomized) have
demonstrated further improvement in patients treated with the ad-
dition of interferon [5] and/or Rituximab [6, 7]. Chemo-immuno-
therapy with subsequent Rituximab maintenance is now consid-
ered the standard treatment of FL.
Material and methods
Radioimmunotherapy protocol and logistics
Since March 2004, 21 follicular lymphoma patients were treat-
ed with Ibritumomab in three PLRG centres in Cracow (n = 17),
Wroclaw (n = 3) and Warsaw (n = 1). Each radioimmunotherapy
centre consists of Departments of Haematology/Oncology and
Nuclear Medicine. Haematologists are responsible for patient
qualification, treatment planning, financing the procedure, care
during post ibritumomab cytopenias and later follow-up. The nu-
clear medicine departments are responsible for 90Y ordering and
handling, performing adequate dosimetry, final drug preparation
and administration. For logistic reasons, the procedure is per-
formed in Poland on Fridays, and the final qualification of patients
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had to be performed at least nine days earlier, to allow for the
ordering, manufacture and transport of yttrium.
In our follicular lymphoma patients, Ibritumomab was given
according to the standard protocol (Figure 1). Its infusion was pre-
ceded by two doses of Rituximab (250 mg/m2), seven days before
and less than four hours before RIT. The final drug was prepared in
the nuclear medicine departments from the commercially available
ibritumomab “cool kit” — antibody and tiuxetan (yttrium chelator)
manufactured by Bayer-Pharma-Schering (BSP), and 90Y isotope
sent from France (CIS bio International, Gif-sur-Yvette Cedex,
France). The standard dose was 14.8 MBq/kg (not exceeding the
maximum dose of 1200 MBq, which meant that each patient over
80 kg had an effective dose reduction). For patients with a mild
thrombocytopenia (100–150 000/ul) or leucopoenia (1500–2000/ul)
protocol requires a dose reduction to 11.1 MBq/kg.
Demographics
The average age of FL patients subjected to radioimmuno-
therapy was 52 (38–67 range). There was a marked female pre-
dominance (14 out of 21). It was 2-6th line of therapy applied in
cases of refractory or relapsing after a Rituximab containing regi-
men. Most of patients were heavily pre-treated; all were in ad-
Table 1. Earlier treatment and tumour burden of patients subjected to RIT
Diagnosis Age Earlier therapies RIT Tumour burdens Response
—  therapy line before RIT to RIT
FL 55 6 ¥ FC, 4 ¥ CHOP, 4 ¥ CHOP-R 4 5.0 PR
TFL 38 VACOP -B, 3 ¥ CHOP-R, 3 ¥ 2CdA-R + ESHAP + DICEP, IFRT 5 4.0 PR
MZL 56 6 ¥ CHOP, 6 ¥ CHOP, 4 ¥ R, 1 ¥ CHOP 4 8.0 PR
SLL 61 7 ¥ COP, INF gamma, 4 ¥ COP-R, 4 ¥ CHOP-R, INF gamma-R 5 4.2 PR
FL 41 LP+1 ¥ COP, 6 ¥ CHOP, 6 ¥ CHOP-R, CTX+ HDT ( BEAM). 5 4.0 PR
MZL 53 6 ¥ COP, 6 ¥ CHOP-R, INFgamma-R 4 7.0 PR
FL 53 3 ¥ COP, 4 ¥ CHOP-R, 3 ¥ FMD-R, IFRT 5 3.5 PR
FL 48 3 ¥ CHOP,3 ¥ CC, INF+R, CTX-R 4 3.0 CR/CRu
FL 44 2 ¥ COP+5 ¥ FCM,  6 ¥ CHOP,  8 ¥ CHOP-Bleo, 2 ¥ 2CdA+ 5 ¥ F, 5 5.0 PR
FL 60 6 ¥ CHOP,  6 ¥ MEVA,  4 ¥ R 4 4.0 CR/CRu
TFL 47 6 ¥ CHOP, 4 ¥ CC-R+ CTX-R 3 2.5 PR
FL 67 8 ¥ CHOP, 4 ¥ R, 4 ¥ FCM-R 4 6.3 CR/CRu
FL 3 ¥ CHOP, 3 ¥ CC, 1 ¥ ESHAP+CHOP-R 3 0.0 CR/CRu
FL 53 6 ¥ COP, 3 ¥ FC-R 3 4.4 CR/CRu
FL 65 Splenectomy 2 3.6 CR/CRu
FL 46 2 ¥ LP, 6 ¥ F-R, 5 ¥ CHOP, 1 ¥ DHAP+1 ¥ CED+1 ¥ VP+PBSCC 5 2.7 PR
FL 67 2 ¥ CHOP,  4 ¥ R,  IFRT 4 1.4 CR/CRu
TFL 54 6 ¥ CVP-R, 2 ¥ CHOP-R + CHOP 3 3.5 PR
FL 44 6 ¥ CVP-R 2 7.0 CR/CRu
FL 46 6 ¥ CHOP, 6 ¥ CVP-R 3 2.8 CR/CRu
FL 56 3 ¥ CHOP, 4 ¥ R, IFRT 4 1.7 CR/CRu
FL — follicular lymphoma; TFL — transformed follicular lymphoma; MZL — marginal zone lymphoma; SLL — small lymphocytic lymphoma; R — rituximab; FC — fludarabine,
cyclophosphamide; CHOP — cyclophosphamide, vincristine, doxorubicin, prednisolone; 2 CdA — cladribine; ESHAP — etoposide, cytarabine, cisplatin, methylprednisolone;
DICEP — cisplatin, cyclophosphamide, methylprednisolone; IFRT — involved field radiotherapy; COP — cyclophosphamide, vincristine, prednisolone; INF gamma — interferon
gamma; LP — chlorambucil, prednisolone; HDT — high dose therapy; BEAM — carmustine, cytarabine, etoposide, melphalan; FMD — fludarabine, mitoxantrone, dexametha-
sone; CC — cyclophosphamide, cladribine; CTX — cyclophosphamide; FCM — fludarabine, cyclophosphamide, mitoxantrone; CHOP-Bleo — cyclophosphamide, vincristine,
doxorubicin, prednisolone, bleomycin; F — fludarabine; MEVA — mitoxantrone, etoposide, vincristine, cytarabine; FC — fludarabine, cyclophosphamide; CED — cyclophospha-
mide, etoposide, dexamethasone; VP — etoposide, prednisolone; PBSCC — peripheral blood stem cell collection
Figure 1. Zevalin treatment protocol in FL patients. *0.4 mCi (15 MBq)/kg when platelet count is ≥ 150,000/mL; 0.3 mCi (11 MBq)/kg when platelet
count is 100,000–150,000/mL; the maximum dose is 1200 Mbq (32 mCi).
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vanced clinical stage with a measurable tumour burden at the
time of RIT. Chemotherapy details are summarized in Table 1.
The first nine patients were part of a “pre registration study” in
which Bayer Schering Pharma (BSP) sponsored the drug for any
patients fulfilling the registration criteria. Although a histopatho-
logical review performed later revealed two cases of marginal zone
lymphoma (MZL) and one case of small lymphocytic lymphoma
(SLL), we decided to include these patients in the survival analy-
sis. In addition — somehow arbitrary — we included three pa-
tients with FL after transformation, where ibritumomab was used
in a consolidation strategy.
Response criteria
Most patients had a later follow-up in one of the local centres;
therefore, the response assessment varied. For the purpose of
this analysis, we defined partial response (PR) as any measur-
able mass visible on imaging studies or bone marrow involve-
ment seen in aspiration biopsy cytology. As a proper differentia-
tion of complete response (CR) from complete response uncon-
firmed (CRu) is not possible without a thorough flow cytometry,
cytogenetics and molecular analysis, we decided to place all oth-
er cases in the CR/CRu category.
Statistical analysis
Statistical analysis was based on the data gathered in March
2006. Both descriptive statistics, plotting Kaplan Meier curves of
progression free and overall survival (PFS, OS) were performed
using Statistica 6 software. A Cox-Mantel test was used to com-
pare the survival curves in sub-group analysis.
Results
Ibritumomab was administered to 21 patients without any major
protocol violations: 17 received 14.8 MBq/kg; in a further four cases
the dose was reduced to 11.1 MBq/kg due to pretreatment mild
thrombocytopenia (100–150 000/ul) or leucopoenia (1500–2000/ul).
Most of the patients experienced some degree of haematological
toxicity: according to WHO grade III and IV, leucopoenia (< 1500
WBC/ul) or thrombocytopenia (< 99 000/ul) was observed in 13/
/21 patients. The onset of cytopenia was postponed and occurred
3–6 weeks (average 4.5) after ibritumomab administration, which
is characteristic for radioimmunotherapy, reflecting its effect on
the STEM cells. Leucopenia lasted 0–15 weeks (2.9 on average):
in five patients it was necessary to use growth factor granulocyte
colony stimulating factor (G-CSF), but none of them developed
serious infections that required treatment in a hospital (three up-
per respiratory tract infections were managed on outpatient ba-
sis). Thrombocytopenia was more pronounced (3.7 weeks, range
0–12), and although platelet transfusions were necessary only in
three patients, most of them had to limit their normal activity dur-
ing that period. Full blood count (FBC) results of 12 patients, whose
RIT and the complete follow-up was performed at Cracow, are
shown in Figure 2. In the first patient, handling ibritumomab be-
fore adequate plastic syringe shields were introduced caused lo-
cal radiation related skin burns. During the follow-up, one case of
myelodysplastic syndrome was reported 21 months after radio-
immunotherapy: a rare side effect described in 1.5–2 % of pa-
tients 2–10 years after RIT [8].
All patients demonstrated an objective response to radioim-
munotherapy (10 CR/CRu and 11 PR) lasting longer than re-
sponses after the previous therapy in 17 out of 21 cases. Four
patients with a shorter time to progression were earlier subject-
ed to an intensive therapy protocols (Zevalin — Carmustine, Cyt-
arabine, Etoposide, Melphalan Z–BEAM transplant, 3 cycles of II
line intensive chemotherapy or chemotherapy Cyclophospha-
mide, Doxorubicin, Vincristine, Prednisolon-Rituximab CHOP-R).
Progression free survival (PFS) and OS (overall survival) are dem-
onstrated on Kaplan Meier curves (Figure 3). The medium PFS
of 15.8 months exceeds the average 12.9 months described in
the literature [9], and median OS was still not reached after 45
months of follow-up.
Patients treated earlier in the course of the disease (2nd–3rd
versus 4th–5th therapy line) had longer progression free survival
(median PFS not yet reached, versus 15.4 months, Cox-Mantel
test: I = 2.068125 U = –3.34494, p = 0.02). With only 21 patients
included in the study, the influence of tumour mass before thera-
py and response to treatment (PR vs. CR/CRu) was not statisti-
cally significant.
The whole radioimmunotherapy procedure consisted of two
outpatient visits, which allowed it to be offered to patients from all
over the country. The expected haematological toxicity was fully
manageable, although regular follow-up in local haematological
departments with full blood count (FBC) analysis was necessary.
For the first two months, until platelet recovery, the patients were
advised not to work. Practically, the only costs were drug-related
Figure 2. Blood platelet (Plt) (A) and white blood cell (WBC) (B) recov-
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(Ibritumomab itself, Ytracis and Rituximab), exceeding 18 700 Euro,
which is comparable to the current standard: 2 years of Rituximab
maintenance therapy.
Discussion
The Polish Lymphoma Research Group (PLRG) results of ra-
dioimmunotherapy in follicular lymphoma patients are fully com-
parable to those previously described in literature. Haematologi-
cal toxicity was moderate and manageable. Treatment related
myelodysplastic syndrome is an important warning, although our
sample is too small to assess its incidence [8].
In Poland, Rituximab has not been registered for follicular lym-
phoma at diagnosis; therefore, the majority of our patients received
sub-optimal first line therapy. Postponing chemoimmunotherapy
until the disease relapsed or until it became refractory further post-
poned radioimmunotherapy. Progression free survival exceeding
15 months is three months longer than in the US registration trials
[9, 10]; medium overall survival (OS) is still not reached after 45
months of observation. This may be explained by excluding pa-
tients with a very large tumour burden, where RIT is less effective.
The largest measurable lymph nodes before treatment were 1.4–
–8 cm (average 4.0 cm) in diameter, and we could not, therefore,
demonstrate a clear correlation between the tumour size and the
treatment effectiveness (Figure 4). Although ibritumomab was giv-
en to most of our patients in the third and further treatment lines,
the better outcome of those treated earlier was statistically signi-
ficant (Figure 5). In our data there was no difference between the
outcome of patients achieving complete or partial regression, but
the patient numbers were low and the CR/CRu category was not
well defined (Figure 6).
Which patients can merit the most from radioimmunothera-
py? Ibritumomab maybe be used in FL algorithms in two different
therapy strategies (Table 2). In the first “cure” is the ultimate, al-
though perhaps unrealistic, target. This optimism is based on long
lasting progression free survival (PFS) (sometimes more than
7 years) demonstrated in US registration studies [11]. The medi-
um PFS increases with the quality of response: it ranges from
12 months in responders, to 23 months in CR/CRu and even
66 months in “true CR” patients [9, 12]. About 20% of responders
and even 40% of those who remained in CR a year after the ibritu-
momab have a plateau on survival curves [13]. Clinical trials with
Tositumomab (a monoclonal antibody conjugated with 131Iodine)
led to similar conclusions. The long lasting responses were
achieved in 20% of responders, and 40% of CR confirmed by
a Masked Independent Randomized Radiology and Oncology Re-
view (MIRROR) panel [14]. Being consequent with this approach,
if all PR patients will eventually relapse, one should do everything
possible to increase the CR rate. This could be achieved either by
applying radioimmunotherapy earlier, before the disease becomes
resistant to therapy, or by using ibritumomab as a consolidation
strategy, after reducing the tumour burden by chemotherapy. The
efficiency of the first approach was demonstrated by Emmanoul-
Figure 3. Overall survival (OS) (A) and progression free survival (PFS)
(B) Kaplan Meier curves of FL patients after RIT.
B
A
Figure 4. Overall survival (OS) (A) and progression free survival (PFS)
(B) Kaplan Meier curves of FL patients after RIT. Subgroup analysis
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ides [15]. Complete regression could be achieved in 62% of pa-
tients treated with ibritumomab at diagnosis, 54% of those in
a first relapse, 40% after the previous 2 lines of therapy and less
than 15% of those treated later. In one of the tositumomab stud-
ies [16], RIT was a consolidation after abbreviated first line CHOP
chemotherapy. Complete regressions were achieved in 57/76
patients, and 40 were still in an on-going CR 3.5–7 years later
(5 year progression free survival (PFS) and overall survival (OS)
were 67% and 87% respectively). Consolidation radioimmunother-
apy cannot be recommended as first line treatment in follicular
lymphoma outside clinical trials because of the very good results
of the present standard Cyclophosphamide, Vincristine, Predniso-
lon-Rituximab (CVP-R) or Cyclophosphamide, Doxorubiccin, Vin-
cristine, Prednisolon-Rituximab (CHOP-R) chemoimmunotherapy
and the uncertainty of long-lasting adverse effects of RIT. Haema-
tological toxicity depends on the direct effect on the stem cells
[17]. Although it is possible to treat relapses after radioimmuno-
Table 2. Possible place of Zevalin in FL therapy algorithm
Intend to “cure” The best “palliation” possible
Relatively early in the course of the disease When? In patients failing several therapy lines
(consolidation of 2nd line therapy?)
Usually as consolidation strategy How? Usually monotherapy
High CR rate and long PFS Main goal? High RR for symptom relief,
good QoL and minimal side effects
therapy with subsequent chemotherapy regimens [18], and even
mobilize the stem cells for transplant purposes, more controlled
studies with upfront radioimmunotherapy are necessary to fully
address this issue.
The second place of ibritumomab in follicular lymphoma is in
optimal palliation therapy for patients failing several other treat-
ment modalities. In these heavily pretreated patients, the safety of
the procedure and the quality of life (QoL) are most important.
Disseminated disease, even when refractory to chemotherapy may
still respond to radioimmunotherapy. Although complete remis-
sions are rare (< 15% of the patients), the response rate is usually
high (over 70%) [15] and the progression free survival exceeds
that achieved after the preceding chemotherapy. Radioimmuno-
therapy is most effective in patients with tumours not exceeding
5–7 cm in size [19].
Ibritumomab radioimmunotherapy is a safe and feasible out-
patient procedure. In typical cases it does not require dosimetry
Figure 5. Overall survival (OS) (A) and progression free survival (PFS)
(B) Kaplan Meier curves of FL patients after RIT. Subgroup analysis
— impact of tumour size before RIT.
A
B
Figure 6. Overall survival (OS) (A) and progression free survival (PFS)
(B) Kaplan Meier curves of FL patients after RIT. Subgroup analysis
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and haematological toxicity may be best predicted by FBC before
the treatment (Figure 2). Although it usually requires from the pa-
tient a change in their lifestyle for 2–3 months after the therapy, it
is an interesting alternative to two year long Rituximab mainte-
nance. In FL, outside controlled clinical trials, we would suggest
considering it relatively early in high risk cases (i.e. a PR after CVP-
R or CHOP-R chemoimmunotherapy) and leaving it for until later
relapses if the risk is low.
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